Mukka Proteins Limited Approves Acquisition to Make Ento Proteins Wholly Owned Subsidiary
Mukka Proteins Limited's Board approved acquiring 1,000 additional equity shares in Ento Proteins Private Limited for Rs. 32.30 lakhs on February 12, 2026, increasing shareholding from 74.01% to 100%. EPPL, a manufacturer of insect meal and insect oil incorporated in 2021, reported turnover of Rs. 7.46 crores and PAT of Rs. 49.47 lakhs in FY 2024-25. The cash acquisition, scheduled for completion by June 30, 2026, aligns with Mukka Proteins' strategy to expand its alternate proteins business segment.

*this image is generated using AI for illustrative purposes only.
Mukka Proteins Limited announced that its Board of Directors has approved the acquisition of additional equity shares in subsidiary company Ento Proteins Private Limited (EPPL) during a meeting held on February 12, 2026. The strategic move will transform EPPL into a wholly owned subsidiary of the fish meal and fish oil manufacturer.
Acquisition Details
The Board approved the acquisition of 1,000 equity shares of face value Rs. 100 each in EPPL for a total consideration of Rs. 32,30,000. The shares will be acquired from existing shareholders through a cash transaction.
| Parameter: | Details |
|---|---|
| Shares Acquired: | 1,000 equity shares |
| Face Value: | Rs. 100 per share |
| Total Consideration: | Rs. 32,30,000 |
| Payment Method: | Cash |
| Completion Timeline: | June 30, 2026 |
Shareholding Structure Changes
The acquisition will significantly alter Mukka Proteins' ownership structure in EPPL, increasing its control substantially.
| Shareholding Metric: | Current | Post-Acquisition | Change |
|---|---|---|---|
| Ownership Percentage: | 74.01% | 100.00% | +25.99% |
| Status: | Subsidiary | Wholly Owned Subsidiary | Enhanced Control |
Target Company Profile
Ento Proteins Private Limited operates in the alternative proteins sector, specializing in insect-based products. The company was incorporated on March 8, 2021, and has demonstrated consistent growth in its business operations.
| Financial Parameter: | Amount |
|---|---|
| Authorized Capital: | Rs. 10,00,000 |
| Paid-up Capital: | Rs. 3,84,700 |
| FY 2024-25 Turnover: | Rs. 7,46,27,305 |
| FY 2024-25 PAT: | Rs. 49,47,474 |
Business Performance Trajectory
EPPL has shown steady revenue growth over the past three years in the insect meal and insect oil manufacturing segment:
| Year: | Turnover |
|---|---|
| March 2023: | Rs. 4,72,20,140 |
| March 2024: | Rs. 6,44,38,907 |
| March 2025: | Rs. 7,46,27,305 |
Strategic Rationale
The acquisition forms part of Mukka Proteins' strategic investment plans to expand its alternate proteins business. EPPL's specialization in insect meal and insect oil manufacturing complements the parent company's existing portfolio in the protein sector. The transaction is being conducted on an arm's length basis, with EPPL classified as a related party due to its subsidiary status.
Regulatory Compliance
The Board meeting, which commenced at 4:00 p.m. and concluded at 4:45 p.m., was conducted in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. No governmental or regulatory approvals are required for completing this acquisition. The company has provided comprehensive disclosures as mandated under Schedule III of the Listing Regulations.
Historical Stock Returns for Mukka Proteins
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.57% | +7.00% | +13.29% | -8.57% | -28.51% | -40.66% |


































